Research: Gene Editing for Lifelong Lipid Control
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Research: Gene Editing for Lifelong Lipid Control
-
Narrated by:
-
By:
About this listen
Steven Nissen, MD, and Luke Laffin, MD, discuss a groundbreaking phase 1 trial of a CRISPR-Cas9 gene-editing therapy targeting ANGPTL3. They explore its potential as a one-time treatment to significantly lower LDL cholesterol and triglycerides, with promising safety and efficacy data that could reshape lipid management.
Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research
Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.